Skip to main content
. 2018 May 22;13(5):e0197315. doi: 10.1371/journal.pone.0197315

Fig 1. Kaplan-Meier estimates of recurrence free survival (RFS) and overall survival (OS).

Fig 1

(A) OS in the entire cohort (n = 104) at 2 years was 87.3% (95% CI, 80.5–94.1%) and 75.6% (95% CI, 65.2–86.0%) at 5 years; ◆ indicates calculated survival probability according to MSKCC nomogram at 4, 8, and 12 years. (B) RFS in the entire cohort at 2 and 5 years was 68.1% (95% CI, 58.5–77.7%) and 61.2% (95% CI, 50.4–71.6%) (C) OS stratified by tumor localization (extremities only cohort 90.5% (95% CI, 83.7–97.3%) and 79.0% (95% CI, 68.4–89.6%) at 2 and 5 years. (D) RFS stratified by tumor localization (extremities only cohort was 74.0% (95% CI, 64.0–84.0%) and 65.3% (95% CI, 53.7–76.9%) at 2 and 5 years.